Effects of Proton Pump Inhibitor Administration and Intake of a Combination of Yogurt and Galactooligosaccharides on Bone and Mineral Metabolism in Rats

Takasugi, Satoshi; Shioyama, Miho; Kitade, Masami; Nagata, Masashi; Yamaji, Taketo

doi:10.3390/nu8100653

Cited by 5 publications

(3 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the results of the effects of PPIs on calcium absorption are inconsistent [17][18][19]. Besides their effects on calcium, IPP might also affect phosphorus as a rat study indicated that PPI administration influenced phosphorus metabolism via a higher phosphorus absorption [20].…”

Section: Overall Biological Plausibility For the Association Between ...mentioning

confidence: 99%

See 1 more Smart Citation

Proton Pump Inhibitors and Bone Health: An Update Narrative Review

Lespessailles

Toumi

2022

IJMS

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are an antacid drug often used in acid-related disorders. They decrease acid secretion in the stomach by blocking an enzyme called H+/K+ ATPase which controls acid production. Introduced to the market in 1989, their use has increased rapidly worldwide and they are now among the top 10 most prescribed drugs in the United States. As of 2015, the FDA has already approved six drugs of this class (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole). Recently, the risks and benefits of long-term PPI use were questioned and many studies indicated that their use should be carefully considered, especially in young patients, whose treatment with these drugs could last many years. Even greater concerns have been raised about a potential positive association between PPIs and osteoporotic fracture risk including the hip, spine and wrist. Although based on observational studies, there is substantial evidence associating the long-term use of PPIs and fracture. This relationship is only partially admitted due to the lack of consistent effects of PPIs on bone mineral density loss. Therefore, this narrative review aimed to discuss the recent findings pertaining to the risk of osteoporotic fracture associated with PPIs, in particular prolonged use, and to call for further research to elucidate the mechanisms associated with this bone fragility.

show abstract

Section: Overall Biological Plausibility For the Association Between ...mentioning

confidence: 99%

“…Other interaction between the effects of PPI and diet have been evidenced in rats [20,21]. In vitro studies have shown that PPIs, namely omeprazole, inhibited bone resorption [22,23] via selective inhibition of osteoclasts vacuolar H + -ATPase [24].…”

Section: Overall Biological Plausibility For the Association Between ...mentioning

confidence: 99%

Proton Pump Inhibitors and Bone Health: An Update Narrative Review

Lespessailles

Toumi

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…8 Others have demonstrated a significant decline in bone mineral density, increased bone resorption and decreased bone formation in rats treated with omeprazole for a few months. [9][10][11] However, these models are not perfect as the animals are not infected with H. pylori. Besides, the data on short-term skeletal effects of triple therapy or PPI are very limited.…”

Section: Introductionmentioning

confidence: 99%

<p>The Skeletal Effects of Short-Term Triple Therapy in a Rat Model of Gastric Ulcer Induced by <em>Helicobacter pylori</em> Infection</p>

Ekeuku

Thong

Fazalda

et al. 2020

DDDT

View full text Add to dashboard Cite

Purpose: Triple therapy is the standard therapy to eradicate Helicobacter pylori (H.pylori) infection. Chronic use of proton pump inhibitors (PPIs), a component of triple therapy, is associated with osteoporosis. However, the skeletal effects of short-term triple therapy containing PPI remain elusive. This study aims to determine the skeletal effect of shortterm triple therapy in a rat model of gastric ulcer induced by H. pylori. Methods: Three-month-old male Sprague Dawley rats were assigned to normal control, H. pylori-inoculated group (negative control) and H. pylori-inoculated group receiving triple therapy consisting of omeprazole [2.035 mg/kg body weight (b.w)], amoxicillin (102.80 mg/kg b.w) and clarithromycin (51.37 mg/kg b.w) (n=6/group). H. pylori infection developed for four weeks after inoculation, followed by two-week triple therapy. At the end of the treatment period, femoral bones of the rats were harvested for analysis. Bone mineral density and content of the femurs were determined using dual-energy X-ray absorptiometry, while bone strength was measured with a universal mechanical tester. Results: Bone mineral content was significantly lower in the negative control group compared to the triple therapy group (p=0.014). Triple therapy decreased strain (vs negative control, p=0.002) and displacement of the femur (vs normal control, p=0.004; vs untreated control, p=0.005). No significant difference was observed in other parameters among the study groups (p>0.05). Conclusion: Short-term triple therapy increases bone mineral content but decreases bone strength of rats. Skeletal prophylaxis should be considered for patients on short-term triple therapy containing PPI.

show abstract